Catalent Increases Investment in Redwood Bioscience - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Increases Investment in Redwood Bioscience


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 4
Catalent has reported that based on data generated by the SMARTag ADC platform, it has increased its minority investment in Redwood Bioscience. The proprietary SMARTag precision protein-chemical engineering platform and toxin-linker technologies developed by Redwood enables the generation of homogeneous antibody-drug conjugates (ADCs) engineered to enhance potency, safety, and stability.

Catalent announced in April 2013 that it had acquired an exclusive license to market the SMARTag technology and has subsequently collaborated with Redwood for the ongoing development and marketing of the technology. Redwood’s new, site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to improve performance and ease of manufacturing. Combined with Catalent’s proprietary GPEx cell line expression system, Catalent recently completed a biomanufacturing Center of Excellence in Madison, Wisconsin and broad range of analytical and fill-finish services to develop more biologic treatments.

Redwood’s protein conjugation and linker technologies overcome the limitations associated with conventional protein chemistries that produce heterogeneous products with variable conjugate potency, toxicity, and stability, according to the company. The SMARTag technology enables site-specific, programmable drug-protein conjugation and uses naturally occurring modifications to proteins requiring minimal cell-line engineering.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here